Reported 29 days ago
Analysts highlight two penny stocks, Regulus Therapeutics (RGLS) and Ventyx Biosciences (VTYX), each poised to potentially rally over 500% in the coming months. RGLS focuses on innovative treatments for kidney diseases and has shown promising early results in clinical trials, while VTYX is developing oral medications for autoimmune and inflammatory disorders, recently gaining investment to advance its clinical efforts. Both stocks hold a 'Strong Buy' consensus rating among analysts, indicating significant upside potential.
Source: YAHOO